Geron Corporation (GERN) financial statements (2022 and earlier)

Company profile

Business Address 919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments184176198211196228219
Cash and cash equivalents35295732104523
Short-term investments149147141179186183196
Restricted cash and investments0000000
Receivables2111111
Other undisclosed current assets1223231
Total current assets:187179202215200232221
Noncurrent Assets
Operating lease, right-of-use asset5555555
Property, plant and equipment1111111
Long-term investments and receivables29394133634646
Long-term investments29394133634646
Other undisclosed noncurrent assets5544222
Total noncurrent assets:39505043715454
TOTAL ASSETS:226229252259271286275
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities45383628302318
Accounts payable7544744
Accrued liabilities30262720151410
Employee-related liabilities8753864
Other undisclosed current liabilities1111111
Total current liabilities:46383729312419
Noncurrent Liabilities
Long-term debt and lease obligation543939292955
Long-term debt, excluding current maturities5035342424  
Operating lease, liability4455555
Other undisclosed noncurrent liabilities(4)   (5)19 
Total noncurrent liabilities:50434334242910
Total liabilities:100828162605329
Stockholders' equity
Stockholders' equity attributable to parent126152176201211233251
Common stock0000000
Additional paid in capital1,3981,3911,3891,3841,3661,3641,362
Accumulated other comprehensive income (loss)(0)000000
Accumulated deficit(1,272)(1,240)(1,213)(1,183)(1,156)(1,132)(1,112)
Total stockholders' equity:126152176201211233251
Other undisclosed liabilities and equity (4)(5)(5)  (5)
TOTAL LIABILITIES AND EQUITY:226229252259271286275

Income statement (P&L) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues1001000
Realized investment gains   1   
Gross profit:1001000
Operating expenses(32)(26)(29)(29)(23)(20)(17)
Other undisclosed operating loss   (1)   
Operating loss:(31)(26)(29)(28)(23)(20)(17)
Nonoperating income0001  0
Investment income, nonoperating0000   
Other nonoperating income (expense)(0)(0)(0)1  0
Interest and debt expense(1)(1)(1)(1)   
Other undisclosed income from continuing operations before equity method investments, income taxes    1  
Loss before gain (loss) on sale of properties:(32)(27)(30)(28)(22)(20)(17)
Other undisclosed net loss    (2)  
Net loss:(32)(27)(30)(28)(24)(20)(17)
Other undisclosed net income attributable to parent     01
Net loss available to common stockholders, diluted:(32)(27)(30)(28)(24)(20)(16)

Comprehensive Income ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(32)(27)(30)(28)(24)(20)(17)
Other undisclosed comprehensive loss(0)   (0)  
Comprehensive loss:(32)(27)(30)(28)(24)(20)(17)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)(0)(0)01
Comprehensive loss, net of tax, attributable to parent:(32)(27)(30)(28)(24)(20)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: